Pazopanib HCL intermediates manufacturer

Pazopanib HCL intermediates
Tel: +86-311-67260775 sales@dingminpharma.com
News
Your location: Home » News

Baricitinib -CAS No.:1187594-09-7 for sale

When should Baricitinib not to be taken? (Contraindications)
Baricitinib should not be used in patients with-
1.  Allergy to baricitinib
2.  Pregnancy and breastfeeding
3.  History of active or severe infection (e.g., Tuberculosis)
4. Blood disorders (e.g., Anemia, low lymphocyte or neutrophil count)
5.  Severe kidney or liver disease
Baricitinib tablets should not be used in children below 18 years of age as their safety and effectiveness have not been studied in the group.
Caution is required while treating patients with-
1.  History of malignancy or cancer
2.  Peptic ulcer or diverticulitis
3.  Presence of blood clots (Deep vein thrombosis, Pulmonary embolism)
What is the dosage of Baricitinib?
1. The recommended adult dose of baricitinib is 2 mg once a day.
2. The maximum dose of baricitinib tablets is 4 mg and can be reduced to 2mg if the disease comes under control.
3. Dose adjustments or modifications should be considered in patients with serious infections or blood disorders such as a decrease in the count of hemoglobin, lymphocytes, and neutrophils.
4. Treatment with baricitinib should be withheld in case of any occurrence of severe infections and must not be continued until the infection is brought under control.
How should Baricitinib be taken?
1. Barcitinib is available in tablet form which should be taken by mouth either with or without food.
2. Take the tablet at any time of the day but stick to the same time each day.
3. Swallow the tablets as a whole with sufficient quantity of water.
Baricitinib
Other Article
PRODUCTS LIST
CONTACT US
Office Address: No.41, Zhaiying South Street, Yuhua District, Shijiazhuang, Hebei Province.China
R&D and Plant Address: Jinzhou Industry Park, Jinzhou County, Shijizhuang, Hebei Province.China
Tel: +86-311-67260775
Fax: +86-311-67591193
sales@dingminpharma.com
Online Service×